XML 15 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
ACQUISITIONS AND PRO FORMA RESULTS (Business Acquisition, Narrative) (Details)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jul. 29, 2019
USD ($)
Feb. 24, 2017
USD ($)
Feb. 23, 2017
USD ($)
Feb. 14, 2017
USD ($)
Dec. 31, 2019
USD ($)
liability
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2019
USD ($)
liability
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Oct. 06, 2017
USD ($)
Business Acquisition [Line Items]                                        
Payment for contingent consideration                                 $ 0 $ 38,196,000 $ 4,661,000  
Cost of goods sold related to fair value inventory purchase accounting adjustments                                 564,681,000 571,496,000 435,511,000  
Realized loss, included in other income, net                           $ 2,300,000            
Deferred tax assets, other         $ 5,900,000       $ 8,835,000               5,900,000 8,835,000    
Net income         15,319,000 $ (27,610,000) $ 29,736,000 $ 32,756,000 25,138,000 $ 13,295,000 $ 11,376,000 $ 10,992,000         $ 50,201,000 60,801,000 64,743,000  
BioD Morselized Amniotic Membrane Based Products | Product Concentration Risk                                        
Business Acquisition [Line Items]                                        
Revenue from product, percentage                                 1.00%      
Codman Specialty Surgical                                        
Business Acquisition [Line Items]                                        
Aggregate purchase price received                                       $ 46,400,000
Assets provided upon termination of transitional supply agreement liability                         $ 1,300,000           1,300,000  
Codman Specialty Surgical | Disposal Group, Held-for-sale, Not Discontinued Operations                                        
Business Acquisition [Line Items]                                        
Gain on sale of business, included in other income, net                                     2,600,000  
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition                                        
Business Acquisition [Line Items]                                        
Net income                                     24,900,000  
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition | Derma Sciences                                        
Business Acquisition [Line Items]                                        
Net income     $ 2,900,000                                  
Arkis                                        
Business Acquisition [Line Items]                                        
Purchase price of business combination $ 30,900,000                                      
Contingent consideration, liability 25,500,000                                      
Contingent consideration, fair value $ 13,100,000       14,200,000                       $ 14,200,000      
Acquired intangible assets, discount rate 14.50%                                      
Deferred taxes $ 1,535,000                                      
Arkis | Milestone Payment One                                        
Business Acquisition [Line Items]                                        
Contingent consideration, liability 10,000,000                                      
Arkis | Milestone Payment Two                                        
Business Acquisition [Line Items]                                        
Contingent consideration, liability $ 15,500,000                                      
Codman                                        
Business Acquisition [Line Items]                                        
Purchase price of business combination       $ 1,014,000,000.000                                
Amounts accrued for ancillary and service agreement         2,100,000       22,800,000               2,100,000 22,800,000    
Cash received from working capital adjustment related to business acquisition                                   26,700,000    
Purchase price adjustment                   (800,000)         $ 3,200,000     3,964,000    
Purchase price, working capital adjustments                             6,200,000          
Purchase price, inventory adjustments                             $ 3,000,000.0          
Purchase price, property, plant and equipment adjustment                   5,500,000                    
Payment for contingent consideration                               $ 15,900,000        
Write off of construction in progress                         6,300,000              
Codman | Fair Value Adjustment to Inventory                                        
Business Acquisition [Line Items]                                        
Cost of goods sold related to fair value inventory purchase accounting adjustments                                   17,300,000    
Codman | Completed technology                                        
Business Acquisition [Line Items]                                        
Purchase price, intangible asset adjustment                   $ 4,700,000                    
Derma Sciences                                        
Business Acquisition [Line Items]                                        
Purchase price of business combination   $ 210,800,000                                    
Contingent consideration, liability         200,000       $ 200,000               200,000 $ 200,000    
Contingent consideration, fair value   37,174,000                                    
Payment of closing expenses   4,800,000                                    
Payment of stock plan settlement   4,300,000                                    
Payments to acquire business   201,700,000                                    
Deferred taxes   $ 14,524,000     14,500,000                       14,500,000      
Deferred tax assets, operating loss carryforwards         39,700,000                       39,700,000      
Deferred tax assets, goodwill and intangible assets         16,400,000                       16,400,000      
Deferred tax liabilities, intangible assets         41,100,000                       41,100,000      
Deferred tax assets, other         $ 500,000                       $ 500,000      
Adjustment, deferred tax assets                         $ 3,300,000 $ 1,500,000         $ 3,300,000  
Number of contingent liabilities remaining | liability         1                       1      
Contingent consideration arrangements, maximum payout         $ 3,000,000.0                       $ 3,000,000.0      
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments                                        
Business Acquisition [Line Items]                                        
Payment for contingent consideration                                 $ 33,300,000